Clinical Trial Search

Primary: Progression Free Survival (PFS) — 6.34; 6.74 Months — p=0.698

Primary: Total Number of Smoke-free Days (Biochemically Verified) During a 7-day Quit Attempt. — 3.6; 3.7 days

Primary: Percentage of Subjects With Any Component of a Major Morbidity Composite — 68; 58 Participants

Primary: Change From Baseline Bacterial Culture — 30; 16; 26; 29 cultures — p=0.002

Primary: Percentage of Participants Who Achieve Disease Control Rate (DCR) Which Includes Complete Response (CR), Complete Response Unconfirmed (CRu), Partial Response (PR) or…

Primary: Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS). — 1; 0; 0; 2 Participants

Primary: Change From Baseline in Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 3 — 1.39 Standard Deviation Score…

Primary: Percentage of Participants Reaching Disease Free Survival — 45.8 percentage of participants

Primary: Number of Participants With Adverse Events — 10; 4; 1; 20 Participants

Primary: Dose-Limiting Toxicity (DLT) of MK-3475 in Combination With Trastuzumab — 0; 0 Participants

Primary: Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 — 96.30; 16.30; 4.62; 1.43 Minutes

Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) — 51.0 percentage of…

Primary: Feasibility of Retaining Participants in Trial — 100; 86.7 percentage that completed study

Primary: Progression-Free Survival (PFS) as Determined by Investigator's Tumor Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) — 6.8…

Primary: Overall Response Rate (ORR) by Investigator Assessment — 67.7 Percentage of participants